Evidence map›Paper›PMID 41532768›Full record

SynthesisAntimicrobial agents and chemotherapy2026

A systematic literature review and (network) meta-analysis of the effectiveness of ceftolozane/tazobactam versus aminoglycosides/polymyxins and ceftazidime/avibactam for treating adult patients with multidrug-resistant

Hannah Collings, Medi Stone, Maria Chrysostomou, Alex Hirst, Todd Edward Waldenberg, Emre Yucel, Thomas Iodise

Abstract readSystematic ReviewNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Real-World Antibiotic Strategies for Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hannah CollingsAdelphi Values PROVE, Bollington, United Kingdom.
Medi StoneAdelphi Values PROVE, Bollington, United Kingdom.ORCID 0009-0002-1828-9474
Maria ChrysostomouAdelphi Values PROVE, Bollington, United Kingdom.
Alex HirstAdelphi Values PROVE, Bollington, United Kingdom.
Todd Edward WaldenbergMerck & Co., Inc, Rahway, New Jersey, USA.
Emre YucelMerck & Co., Inc, Rahway, New Jersey, USA.ORCID 0000-0002-6036-9526
Thomas IodiseMerck & Co., Inc, Rahway, New Jersey, USA.

Funding

Merck & Co.
6 · The paper itself

Abstract

Multidrug-resistantant (MDR)

Indexed as

AminoglycosidesAnti-Bacterial AgentsAzabicyclo CompoundsCeftazidimeCephalosporinsPenicillanic AcidPolymyxinsPseudomonas aeruginosaPseudomonas InfectionsAdultDrug CombinationsDrug Resistance, Multiple, BacterialHumansTazobactamThird Generation CephalosporinsTreatment OutcomeAminoglycosidesAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsCeftazidimeceftolozane, tazobactam drug combinationCephalosporinsDrug CombinationsPenicillanic AcidPolymyxinsTazobactamThird Generation Cephalosporinsaminoglycosides/polymyxinsceftazidime/avibactamceftolozane/tazobactamC/TMDR-P. aeruginosanetwork meta-analysis

Identifiers

PMID41532768
PMCPMC12888884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.